Priming BCL-2 to kill: the combination therapy of tamoxifen and ABT-199 in ER+ breast cancer.
about
Risk determination and prevention of breast cancerDifferences in clinical importance of Bcl-2 in breast cancer according to hormone receptors status or adjuvant endocrine therapy.Bcl-2 promotes metastasis through the epithelial-to-mesenchymal transition in the BCap37 medullary breast cancer cell line.
P2860
Priming BCL-2 to kill: the combination therapy of tamoxifen and ABT-199 in ER+ breast cancer.
description
2013 nî lūn-bûn
@nan
2013 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Priming BCL-2 to kill: the com ...... ABT-199 in ER+ breast cancer.
@ast
Priming BCL-2 to kill: the com ...... ABT-199 in ER+ breast cancer.
@en
type
label
Priming BCL-2 to kill: the com ...... ABT-199 in ER+ breast cancer.
@ast
Priming BCL-2 to kill: the com ...... ABT-199 in ER+ breast cancer.
@en
prefLabel
Priming BCL-2 to kill: the com ...... ABT-199 in ER+ breast cancer.
@ast
Priming BCL-2 to kill: the com ...... ABT-199 in ER+ breast cancer.
@en
P2860
P356
P1476
Priming BCL-2 to kill: the com ...... ABT-199 in ER+ breast cancer.
@en
P2093
Anthony Letai
P2860
P2888
P356
10.1186/BCR3568
P577
2013-01-01T00:00:00Z
P5875
P6179
1053185154